Noile-Immune Biotech Inc.

TSE:4893 Stock Report

Market Cap: JP¥7.5b

Noile-Immune Biotech Past Earnings Performance

Past criteria checks 0/6

Noile-Immune Biotech's earnings have been declining at an average annual rate of -15.6%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been declining at an average rate of 27.3% per year.

Key information

-15.6%

Earnings growth rate

-11.0%

EPS growth rate

Biotechs Industry Growth31.9%
Revenue growth rate-27.3%
Return on equity-19.6%
Net Margin-319.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

We're Not Very Worried About Noile-Immune Biotech's (TSE:4893) Cash Burn Rate

Sep 17
We're Not Very Worried About Noile-Immune Biotech's (TSE:4893) Cash Burn Rate

Here's Why We're Not Too Worried About Noile-Immune Biotech's (TSE:4893) Cash Burn Situation

Apr 17
Here's Why We're Not Too Worried About Noile-Immune Biotech's (TSE:4893) Cash Burn Situation

Revenue & Expenses Breakdown

How Noile-Immune Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSE:4893 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24307-980460783
31 Mar 24310-976449666
31 Dec 23316-1,130404646
30 Sep 23319-1,268400569
31 Dec 22625-386390334
31 Dec 21100-795330514
31 Dec 2097-636285413

Quality Earnings: 4893 is currently unprofitable.

Growing Profit Margin: 4893 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4893 is unprofitable, and losses have increased over the past 5 years at a rate of 15.6% per year.

Accelerating Growth: Unable to compare 4893's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4893 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).


Return on Equity

High ROE: 4893 has a negative Return on Equity (-19.58%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies